Evotec and Novo Nordisk Collaborate to Develop Breakthrough Off-the-Shelf Cell Therapies for Future Commercialization
Portfolio Pulse from Benzinga Newsdesk
Evotec and Novo Nordisk have announced a partnership to develop off-the-shelf cell therapies. Novo Nordisk will fund technology development at Evotec's facilities, with an option for exclusive rights in a specific therapeutic area. Evotec will receive R&D funding, upfront, milestone, and royalty payments.
September 26, 2024 | 6:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evotec has partnered with Novo Nordisk to develop off-the-shelf cell therapies, receiving R&D funding and potential milestone and royalty payments.
The partnership with Novo Nordisk is likely to positively impact Evotec's stock due to the funding and potential future revenue from milestone and royalty payments. The collaboration enhances Evotec's position in the cell therapy market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90